Androgen deprivation therapy

European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer

The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...

Apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer: final survival results from SPARTAN, a phase III trial

SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...

Darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer: overall survival results of phase III ARAMIS study

Darolutamide ( Nubeqa ) is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men...

IPATential150 study: Ipatasertib in combination with Abiraterone and Prednisone / Prednisolone met its co-primary endpoint of radiographic progression free survival in patients with PTEN loss tumours

Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...

Erleada for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease, European Commission approved

The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen...

Apalutamide improves overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer

Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical...

Prostate cancer: hormone therapy may raise risk of Alzheimer's, dementia

For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...

Olaparib in combination with Abiraterone delays disease progression in metastatic castration-resistant prostate cancer

Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...

Safety data from a phase II trial of Radium-223 dichloride plus Enzalutamide versus Enzalutamide alone in men with metastatic castration refractory prostate cancer

Radium-223 dichloride ( Ra-233; Xofigo ), a bone targeting alpha radiopharmaceutical, and Enzalutamide ( Xtandi ), are approved for metastatic...

Enzalutamide prolongs urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer

The PROSPER trial has shown a clinically and statistically significant improvement in metastasis-free survival ( hazard ratio, HR=0.292 [ 95%...

PROSPER trial: Enzalutamide reduces the risk of metastasis or death by 71% in men with non-metastatic castration-resistant prostate cancer

The results from the phase 3 PROSPER trial in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CRPC...

SPARTAN trial, Apalutamide, an androgen receptor inhibitor, improves median metastasis-free survival by more than two years in patients with non-metastatic castration-resistant prostate cancer

New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San...

Prostate cancer: link between androgen deprivation therapy and dementia

A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (...

Abiraterone acetate provides significant clinical benefit in patients with high-risk metastatic hormone-naïve prostate cancer, improving overall survival and radiographic progression-free survival

Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with...